Hisashi Fujioka

Hisashi Fujioka

Auto-generated profile, based on publicly available information

Hisashi Fujioka

Cryo-Electron Microscopy Core Case, School of Medicine, Western Reserve University

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2009 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
ITIryna Tsarukyanova
Iryna Tsarukyanova
JDJudy A. Drazba
Judy A. Drazba
HFHisashi Fujioka
Hisashi Fujioka
SYSatya P. Yadav
Satya P. Yadav
TSTobili Sam-Yellowe
Tobili Sam-Yellowe

13 December 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
WWWenzhang Wang
Wenzhang Wang
XMXiaopin Ma
Xiaopin Ma
SBSabina Bhatta
Sabina Bhatta
CSChangjuan Shao
Changjuan Shao
FZFanpeng Zhao
Fanpeng Zhao
XZXiongwei Zhu
Xiongwei Zhu
Mitochondrial dysfunction plays a critical role in the pathogenesis of Alzheimer’s disease (AD). Mitochondrial proteostasis regulated by chaperones and proteases in each compartment of mitochondria is critical for mitochondrial function, and it is suspected that mitochondrial proteostasis deficits may be involved in mitochondrial dysfunction in AD. In this study, we identified LONP1, an ATP-dependent protease in the matrix, as a top Aβ42 interacting mitochondrial protein through an unbiased screening and found significantly decreased LONP1 expression and extensive mitochondrial proteostasis deficits in AD experimental models both in vitro and in vivo, as well as in the brain of AD patients. Impaired METTL3-m 6 A signaling contributed at least in part to Aβ42-induced LONP1 reduction. Moreover, Aβ42 interaction with LONP1 impaired the assembly and protease activity of LONP1 both in vitro and in vivo. Importantly, LONP1 knockdown caused mitochondrial proteostasis deficits and dysfunction in neurons, while restored expression of LONP1 in neurons expressing intracellular Aβ and in the brain of CRND8 APP transgenic mice rescued Aβ-induced mitochondrial deficits and cognitive deficits. These results demonstrated a critical role of LONP1 in disturbed mitochondrial proteostasis and mitochondrial dysfunction in AD and revealed a mechanism underlying intracellular Aβ42-induced mitochondrial toxicity through its impact on LONP1 and mitochondrial proteostasis.

21 May 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YKYeojung Koh
Yeojung Koh
EVEdwin Vázquez-Rosa
Edwin Vázquez-Rosa
FGFarrah Gao
Farrah Gao
HLHongyun Li
Hongyun Li
SCSuwarna Chakraborty
Suwarna Chakraborty
APAndrew A Pieper
Andrew A Pieper
Alzheimer’s disease (AD) and traumatic brain injury (TBI) are currently untreatable neurodegenerative disorders afflicting millions of people worldwide. These conditions are pathologically related, and TBI is one of the greatest risk factors for AD. Although blood–brain barrier (BBB) disruption drives progression of both AD and TBI, strategies to preserve BBB integrity have been hindered by lack of actionable targets. Here, we identify 15-hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme that catabolizes eicosanoids and other anti-inflammatory mediators, as a therapeutic candidate that protects the BBB. We demonstrate that 15-PGDH is enriched in BBB-associated myeloid cells and becomes markedly elevated in human and mouse models of AD and TBI, as well as aging, another major risk factor for AD. Pathological increase in 15-PGDH correlates with pronounced oxidative stress, neuroinflammation, and neurodegeneration, alongside profound BBB structural degeneration characterized by astrocytic endfeet swelling and functional impairment. Pharmacologic inhibition or genetic reduction of 15-PGDH in AD and TBI models strikingly mitigates oxidative damage, suppresses neuroinflammation, and restores BBB integrity. Most notably, inhibiting 15-PGDH not only halts neurodegeneration but also preserves cognitive function at levels indistinguishable from healthy controls. Remarkably, these neuroprotective effects in AD are achieved without affecting amyloid pathology, underscoring a noncanonical mechanism for treating AD. In a murine microglia cell line exposed to amyloid beta oligomer, major protection was demonstrated by multiple anti-inflammatory substrates that 15-PGDH degrades. Thus, our findings position 15-PGDH inhibition as a broad-spectrum strategy to protect the BBB and thereby preserve brain health and cognition in AD and TBI.

1 November 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
YFYe Fang
Ye Fang
Helene lemieuxHelene lemieux
Helene lemieux
CHCharles Hoppel
Charles Hoppel
RHRichard W. Hanson
Richard W. Hanson
PHParvin Hakimi
Parvin Hakimi
ESEd Stavnezer
Ed Stavnezer
Overexpression of the Ski oncogene induces oncogenic transformation of chicken embryo fibroblasts (CEFs). However, unlike most other oncogene-transformed cells, Ski-transformed CEFs (Ski-CEFs) do not display the classical Warburg effect. On the contrary, Ski transformation reduced lactate production and glucose utilization in CEFs. Compared with CEFs, Ski-CEFs exhibited enhanced TCA cycle activity, fatty acid catabolism through β-oxidation, glutamate oxidation, oxygen consumption, as well as increased numbers and mass of mitochondria. Interestingly, expression of PPARγ, a key transcription factor that regulates adipogenesis and lipid metabolism, was dramatically elevated at both the mRNA and protein levels in Ski-CEFs. Accordingly, PPARγ target genes that are involved in lipid uptake, transport, and oxidation were also markedly up-regulated by Ski. Knocking down PPARγ in Ski-CEFs by RNA interference reversed the elevated expression of these PPARγ target genes, as well as the shift to oxidative metabolism and the increased mitochondrial biogenesis. Moreover, we found that Ski co-immunoprecipitates with PPARγ and co-activates PPARγ-driven transcription.

10 November 1999 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
KZKunyan Zhang
Kunyan Zhang
HFHisashi Fujioka
Hisashi Fujioka
CLCheryl-Ann Lobo
Cheryl-Ann Lobo
DKDwip Kitayaporn
Dwip Kitayaporn
MAMasanori Aikawa
Masanori Aikawa
NKNirbhay Kumar
Nirbhay Kumar

1 February 2025 in The Journal of Immunology
Verified
Journal Article
Closed access
JGJu Gao
Ju Gao
MDMao Ding
Mao Ding
YXYanbin Xiyang
Yanbin Xiyang
SQSiyue Qin
Siyue Qin
DSDevanshi Shukla
Devanshi Shukla
XWXinglong Wang
Xinglong Wang
Mitochondrial antiviral-signaling protein (MAVS) is a key adapter protein required for inducing type I interferons (IFN-Is) and other antiviral effector molecules. The formation of MAVS aggregates on mitochondria is essential for its activation; however, the regulatory mitochondrial factor that mediates the aggregation process is unknown. Our recent work has identified the protein Aggregatin as a critical seeding factor for β-amyloid peptide aggregation. Here we show that Aggregatin serves as a cross-seed for MAVS aggregates on mitochondria to orchestrate innate immune signaling. Aggregatin is primarily localized to mitochondria in the cytosol and has the ability to induce MAVS aggregation and MAVS-dependent IFN-I responses alone in both HEK293 cells and human leukemia monocytic THP-1 cells. Mitochondrial Aggregatin level increases upon viral infection. Also, Aggregatin knockout suppresses viral infection-induced MAVS aggregation and IFN-I signal cascade activation. Nemo-like kinase is further identified as a kinase phosphorylating Aggregatin at Ser59 to regulate its stability and cross-seeding activity. Collectively, our finding reveals an important physiological function of Aggregatin in innate immunity by cross-seeding MAVS aggregation.